Imago BioSciences Inc.

05/12/2022 | Press release | Distributed by Public on 05/12/2022 08:39

Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the[...]